21 research outputs found
Impact of minimal residual disease detection by next-generation flow cytometry in multiple myeloma patients with sustained complete remission after frontline therapy
Minimal residual disease (MRD) was monitored in 52 patients with sustained CR (≥2 years) after frontline therapy using next-generation flow (NGF) cytometry. 25% of patients initially MRD- reversed to MRD+. 56% of patients in sustained CR were MRD+; 45% at the level of 10−5; 17% at 10−6. All patients who relapsed during follow-up were MRD+ at the latest MRD assessment, including those with ultra-low tumor burden. MRD persistence was associated with specific phenotypic profiles: higher erythroblasts’ and tumor-associated monocytes/macrophages’ predominance in the bone marrow niche. NGF emerges as a suitable method for periodic, reproducible, highly-sensitive MRD-detection at the level of 10−6
Combined near-infrared and x-ray diffraction investigation of the octahedral sheet composition of palygorskite
The octahedral composition of palygorskite in more than 300 samples from the Pefkaki deposit, W. Macedonia, Greece, has been studied by near-infrared (NIR) and X-ray diffraction (XRD), and evaluated according to the formula yMgSiO (OH)·xMgFe SiO(OH)·(1-x-y) MgAlSiO (OH). Included in the study were PFI-1 and several commercial palygorskites. Our analysis of 2nd derivative NIR spectra shows that the dioctahedral composition is adequately described by three sharp overtone bands representing AlAlOH, AlFeOH and FeFeOH in M2 dioctahedral sites, and that the summed intensity of these bands is proportional to the amount of dioctahedral component present (1-y). The samples show large variations in the degree of dioctahedral Fe-for-Al substitution with Fe occupying up to 70% of the dioctahedral M2 sites. Ternary analysis shows that the distribution of dioctahedral Al and Fe is not random, but displays a tendency towards homoionic pairing. An overtone band at 7214 cm and several combination bands are indicative of a trioctahedral MgOH component (y), and their appearance correlates with a distinct palygorskite signature in thermogravimetric analysis. Nevertheless, these bands cannot be used reliably for the quantification of a trioctahedral palygorskite component due to their close similarity to those of sepiolite. To circumvent this problem, we have evaluated y indirectly by calculating the difference between 1-y and the total concentration of palygorskite determined by the normalized intensity of the d XRD peak of palygorskite at 10.4 Å. Using this methodology, we have found that the samples conform to a trioctahedral limit of y ≈ 0.55, although within this limit they display large variations in octahedral character. Finally, we extend the above methodology to PLS chemometrics and show how NIR can be used to determine palygorskite content routinely in multimineralic geological samples
Combined Near-infrared and X-ray Diffraction Investigation of the Octahedral Sheet Composition of Palygorskite
Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose
Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose
Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers
The aim of this study was to investigate the kinetics of neutralizing
antibodies (NAbs) and anti-SARS-CoV-2 anti-S-RBD IgGs up to three months
after the second vaccination dose with the BNT162b2 mRNA vaccine. NAbs
and anti-S-RBD levels were measured on days 1 (before the first vaccine
shot), 8, 22 (before the second shot), 36, 50, and three months after
the second vaccination (D111) (NCT04743388). 283 health workers were
included in this study. NAbs showed a rapid increase from D8 to D36 at a
constant rate of about 3% per day and reached a median (SD) of 97.2%
(4.7) at D36. From D36 to D50, a slight decrease in NAbs values was
detected and it became more prominent between D50 and D111 when the rate
of decline was determined at -0.11 per day. The median (SD) NAbs value
at D111 was 92.7% (11.8). A similar pattern was also observed for
anti-S-RBD antibodies. Anti-S-RBDs showed a steeper increase during
D22-D36 and a lower decline rate during D36-D111. Prior COVID-19
infection and younger age were associated with superior antibody
responses over time. In conclusion, we found a persistent but declining
anti-SARS-CoV-2 humoral immunity at 3 months following full vaccination
with BNT162b2 in healthy individuals
Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222
Along with their level of protection against COVID-19, SARS-CoV-2-specific antibodies decline over time following vaccination with BNT162b2. However, relevant data on AZD1222 are scarce. In this context, the aim of this study was to compare SARS-CoV-2 neutralizing antibody (NAb) levels at one, three and six months after second vaccination with the BNT162b2 mRNA vaccine and the ChAdOx1 (AZD1222) viral vector vaccine (NCT04743388). The measurements were performed with the GenScript’s cPassTM SARS-CoV-2 NAbs Detection Kit (GenScript, Inc.; Piscataway, NJ, USA). Overall, data from 282 individuals were included (BNT162b2 n = 83, AZD1222 n = 199). Both vaccines induced strong NAbs responses at 1 month following vaccination. Interestingly, NAb activity seemed superior with BNT162b2 compared with AZD1222. A gradual decline in NAbs titers was evident at 3 and 6 months post vaccination with both vaccines. However, the superiority of NAb response with BNT162b2 over AZD1222 remained consistent at all time points examined. Furthermore, the elimination rate of the NAb titer was higher throughout during the study period for those vaccinated with AZD1222 compared with BNT162b2. Age, gender, body mass index or comorbidities did not have a significant impact on NAbs levels over time. Our results may inform public health policies regarding the timing of booster COVID-19 vaccine shots
Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study
Emerging data suggest suboptimal antibody responses to COVID-19 vaccination in patients with hematological malignancies. We evaluated the humoral response following the BNT162b2 vaccine in patients with chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), and Hodgkin’s lymphoma (HL). An FDA-approved, ELISA-based methodology was implemented to evaluate the titers of neutralizing antibodies (NAbs) against SARS-CoV-2 on day 1 of the first vaccine, and afterwards on day 22 and 50. One hundred and thirty-two patients with CLL/lymphomas and 214 healthy matched controls vaccinated during the same period, at the same center were enrolled in the study (NCT04743388). Vaccination with two doses of the BNT162b2 vaccine led to lower production of NAbs against SARS-CoV-2 in patients with CLL/lymphomas compared with controls both on day 22 and on day 50 (p < 0.001 for all comparisons). Disease-related immune dysregulation and therapy-related immunosuppression are involved in the low humoral response. Importantly, active treatment with Rituximab, Bruton’s tyrosine kinase inhibitors, or chemotherapy was an independent prognostic factor for suboptimal antibody response. Patients with HL showed superior humoral responses to the NHL/CLL subgroups. In conclusion, patients with CLL/lymphomas have low humoral response following COVID-19 vaccination, underlining the need for timely vaccination ideally during a treatment-free period and for continuous vigilance on infection control measures
Predictive Factors for Neutralizing Antibody Levels Nine Months after Full Vaccination with BNT162b2: Results of a Machine Learning Analysis
Vaccination against SARS-CoV-2 with BNT162b2 mRNA vaccine plays a critical role in COVID-19 prevention. Although BNT162b2 is highly effective against COVID-19, a time-dependent decrease in neutralizing antibodies (NAbs) is observed. The aim of this study was to identify the individual features that may predict NAbs levels after vaccination. Machine learning techniques were applied to data from 302 subjects. Principal component analysis (PCA), factor analysis of mixed data (FAMD), k-means clustering, and random forest were used. PCA and FAMD showed that younger subjects had higher levels of neutralizing antibodies than older subjects. The effect of age is strongest near the vaccination date and appears to decrease with time. Obesity was associated with lower antibody response. Gender had no effect on NAbs at nine months, but there was a modest association at earlier time points. Participants with autoimmune disease had lower inhibitory levels than participants without autoimmune disease. K-Means clustering showed the natural grouping of subjects into five categories in which the characteristics of some individuals predominated. Random forest allowed the characteristics to be ordered by importance. Older age, higher body mass index, and the presence of autoimmune diseases had negative effects on the development of NAbs against SARS-CoV-2, nine months after full vaccination
Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study
Simple Summary The urgency of the COVID-19 pandemic has led to
accelerated vaccine development within less than a year. Emerging data
suggest that the ability of patients with hematological malignancies to
form an adequate number of antibodies in response to vaccination for
SARS-CoV-2 is suboptimal. In this context, we evaluated the ability of
132 patients with Chronic Lymphocytic Leukemia, Non-Hodgkin's Lymphoma
and Hodgkin's Lymphoma to elicit an adequate immune response to the
BNT162b2 vaccine. Vaccination with two doses of the BNT162b2 vaccine led
to lower production of neutralizing antibodies against SARS-CoV-2 in
these patients compared with healthy controls. Being on active treatment
for the underlying disease was an independent prognostic factor for
suboptimal antibody response. This finding underlines the need for
timely vaccination ideally during a treatment-free period and for
continuous vigilance on infection control measures. Emerging data
suggest suboptimal antibody responses to COVID-19 vaccination in
patients with hematological malignancies. We evaluated the humoral
response following the BNT162b2 vaccine in patients with chronic
lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), and Hodgkin's
lymphoma (HL). An FDA-approved, ELISA-based methodology was implemented
to evaluate the titers of neutralizing antibodies (NAbs) against
SARS-CoV-2 on day 1 of the first vaccine, and afterwards on day 22 and
50. One hundred and thirty-two patients with CLL/lymphomas and 214
healthy matched controls vaccinated during the same period, at the same
center were enrolled in the study (NCT04743388). Vaccination with two
doses of the BNT162b2 vaccine led to lower production of NAbs against
SARS-CoV-2 in patients with CLL/lymphomas compared with controls both on
day 22 and on day 50 (p < 0.001 for all comparisons). Disease-related
immune dysregulation and therapy-related immunosuppression are involved
in the low humoral response. Importantly, active treatment with
Rituximab, Bruton's tyrosine kinase inhibitors, or chemotherapy was an
independent prognostic factor for suboptimal antibody response. Patients
with HL showed superior humoral responses to the NHL/CLL subgroups. In
conclusion, patients with CLL/lymphomas have low humoral response
following COVID-19 vaccination, underlining the need for timely
vaccination ideally during a treatment-free period and for continuous
vigilance on infection control measures